Safety of gefitinib in non-small cell lung cancer treatment (Q38841473)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on 21 May 2016

Language	Label	Description	Also known as
English	Safety of gefitinib in non-small cell lung cancer treatment	scientific article published on 21 May 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

1 reference

Europe PubMed Central

Safety of gefitinib in non-small cell lung cancer treatment (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Emily Han-Chung Hsiue

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212579%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

James Chih-Hsin Yang

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212579%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

Jih-Hsiang Lee

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212579%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Chia-Chi Lin

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212579%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

language of work or name

0 references

publication date

21 May 2016

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Expert Opinion on Drug Safety

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212579%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212579%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212579%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

993-1000

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212579%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Mechanisms of cutaneous toxicities to EGFR inhibitors.

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Paronychia Induced by Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Severe acute interstitial pneumonia and gefitinib

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Lessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations.

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Rociletinib in EGFR-mutated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Differences in adverse events between 250mg daily gefitinib and 150mg daily erlotinib in Japanese patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

1 reference

https://api.crossref.org/works/10.1080%2F14740338.2016.1192605

21 January 2018

Identifiers

10.1080/14740338.2016.1192605

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212579%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212579%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38841473&oldid=1789770795"